Results 201 to 210 of about 72,605 (256)
Cancer Reports, Volume 9, Issue 5, May 2026.ABSTRACT Background Oropharyngeal squamous cell carcinoma (OPSCC) accounts for a substantial proportion of head and neck cancers, with a rising incidence largely driven by human papillomavirus (HPV) infection. Despite advances in multimodal treatment, disease recurrence remains common and limits long‐term survival, highlighting the need for reliable ...
Yunxia Chen +7 more
wiley +1 more source
Computational Design of an mRNA Vaccine Targeting LRP6 for Triple‐Negative Breast Cancer Therapy
Cancer Reports, Volume 9, Issue 5, May 2026.ABSTRACT Background Triple‐negative breast cancer (TNBC) presents a poorer prognosis than other breast cancer subtypes, attributed to its aggressive nature and the lack of specific therapeutic interventions. TNBC has high recurrence rates and limited survival despite current therapies, emphasizing the critical need for improved treatment options.
Pooriya Teimoori, Mohammadreza Heidari
wiley +1 more source
Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.ABSTRACT Background Cervical cancer remains a significant global health challenge, with squamous cell carcinoma (SCC) and adenocarcinoma representing its predominant histologic types. Programmed death‐ligand 1 (PD‐L1) expression in cervical cancer has been implicated in tumor immune evasion, yet its prognostic significance remains unclear.
Zahra Vahedpoor +5 more
wiley +1 more source
Indicators to identify cancer screening providers with suboptimal case detection: A scoping review
International Journal of Cancer, Volume 158, Issue 9, Page 2339-2358, 1 May 2026.What's new? Quality control of cancer screening programs is essential to maintaining high public health standards. Here, the authors reviewed monitoring of case detection in cervical and colorectal cancer screening programs in Europe, and evaluated its effectiveness. They analysed 20 different measures used for this purpose and showed that many of them
Jiayao Lei +5 more
wiley +1 more source
Predicting optimal impact interventions in the post‐HPV vaccination world
International Journal of Cancer, Volume 158, Issue 9, Page 2262-2271, 1 May 2026.Abstract Prophylactic vaccination is a powerful tool that changes exposure to infections and associated morbidity of preventable diseases. We discuss the impact of pneumococci and human papillomavirus (HPV) vaccination on the population biology of the two micro‐organisms and related public health effects.
Matti Lehtinen +7 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
2020
Human papillomavirus (HPV) is a double stranded DNA (dsDNA) virus that often causes an asymptomatic infection and clears spontaneously. However, HPV infection may result in genital warts, dysplasia, and squamous cell carcinoma of the head, neck and genitalia. Genital HPV is the most common sexually transmitted infection (STI) in the United States.
Amelia B. Thompson, Lisa C. Flowers
+4 more sources
Human papillomavirus (HPV) is a double stranded DNA (dsDNA) virus that often causes an asymptomatic infection and clears spontaneously. However, HPV infection may result in genital warts, dysplasia, and squamous cell carcinoma of the head, neck and genitalia. Genital HPV is the most common sexually transmitted infection (STI) in the United States.
Amelia B. Thompson, Lisa C. Flowers
+4 more sources
2014
Human papillomavirus is an infectious cause of cutaneous neoplasia in humans. Warts can be present on any location on the body and are distributed in a variety of patterns and morphologies. Most warts will resolve spontaneously, while others may progress to cancer.
Amanda Strickland, Gabriela Blanco
openaire +2 more sources
Human papillomavirus is an infectious cause of cutaneous neoplasia in humans. Warts can be present on any location on the body and are distributed in a variety of patterns and morphologies. Most warts will resolve spontaneously, while others may progress to cancer.
Amanda Strickland, Gabriela Blanco
openaire +2 more sources
2018
All males and females without contraindications ages 11-12 years should receive two doses of HPV vaccine administered 6-12 months apart. Vaccination can be started as young as 9 years of age. Those who start the series after the age of 15 should receive three doses of HPV vaccine, with the second and third doses administered 1-2 months and 6 months ...
Matthew Z. Dudley +6 more
openaire +2 more sources
All males and females without contraindications ages 11-12 years should receive two doses of HPV vaccine administered 6-12 months apart. Vaccination can be started as young as 9 years of age. Those who start the series after the age of 15 should receive three doses of HPV vaccine, with the second and third doses administered 1-2 months and 6 months ...
Matthew Z. Dudley +6 more
openaire +2 more sources
Human Papillomavirus (HPV) Entry Inhibitors
2022Chronic or persistent human papillomavirus (HPV) infection is essential for the development of many types of carcinomas, such as cervical carcinoma. Developing new diagnostic and prognostic biomarkers and designing more effective targeted therapeutics and treatment strategies remains urgent.
openaire +2 more sources
Human papillomavirus (HPV) in pregnancy – An update
European Journal of Obstetrics & Gynecology and Reproductive Biology, 2021Human papilloma viruses (HPV) are small epitheliotropic DNA viruses, of which there are 200 genotypes, 40 of which are known to cause genital infections and are also oncogenic. HPV is the most common sexually transmitted infection. Clinical features vary from asymptomatic (identified at routine cervical cancer screening) to large lesions on the vulva ...
Victor N Chilaka +4 more
openaire +2 more sources